Status:

COMPLETED

Step Down Approach in Children With Cow Milk Allergy

Lead Sponsor:

Federico II University

Conditions:

Allergy Milk

Eligibility:

All Genders

Up to 6 years

Phase:

NA

Brief Summary

Cow's milk allergy (CMA) affects up to 3% of European children. In the absence of an alternative to cow's milk, the management of CMA is based on the use of safe, affordable and nutritionally adequate...

Detailed Description

60 Immunoglobulin E-mediated CMA children, consecutively observed at tertiary Centers for Food Allergy, who will meet the inclusion criteria will be invited to participate to the study. Anamnestic, de...

Eligibility Criteria

Inclusion

  • Infants aged \<6 months
  • sure diagnosis of IgE-mediated CMA confirmed by positive oral food challenge for cow's milk and or blood Cow milk protein specific IgE\>0.1kiloUnits/Liter and/or Skin Prick Testing (SPT) for milk wheal size ≥ 3mm
  • children receiving AAF for at least 4 weeks
  • full and stable remission of CMA symptoms.

Exclusion

  • Infant aged \> 6 months,
  • CMP-induced anaphylaxis,
  • evidence of non-IgE-mediated CMA,
  • other food allergies,
  • other allergic diseases,
  • eosinophilic disorders of the gastrointestinal tract,
  • chronic systemic diseases,
  • congenital cardiac defects,
  • active tuberculosis,
  • autoimmune diseases,
  • immunodeficiency,
  • chronic inflammatory bowel diseases,
  • celiac disease,
  • cystic fibrosis,
  • metabolic diseases,
  • malignancy,
  • chronic pulmonary diseases,
  • malformations of the gastrointestinal and/or respiratory tract,
  • administration of prebiotics or probiotics during the 4 weeks before enrolment,
  • use of systemic antibiotics or anti-mycotic drugs during 4 weeks before study entry;
  • investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements;
  • participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study.

Key Trial Info

Start Date :

April 1 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 31 2020

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT03449537

Start Date

April 1 2018

End Date

December 31 2020

Last Update

February 22 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Department of Traslational Medical Science - University of Naples Federico II

Naples, Italy, 80131